Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 + adebrelimab + bevacizumab vs sintilimab or atezolizumab + bevacizumab for first-line advanced hepatocellular carcinoma
CTR20243670Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CS1002, adebrelimab, bevacizumab, sintilimab, atezolizumab in hepatocellular carcinoma (HCC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Nov 2024; status: active.
02
Drugs
CS1002adebrelimabbevacizumabsintilimabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20243670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243670.